August 1, 2011
Two pieces of bio-tech waste are being more heavily pumped amongst today's promoted offerings. Regncocell Therapeutics (RCLL), a pretend "leader in adult stem cell therapy" is run by penny stock specialist, James Mongiardo, and makes enough preposterous claims to provoke us to make them the subject of our next advisory, which we'll start on right after we release our advisory on AURI later this morning.
On the other hand, Amarantus (AMBS) is run by professional sport fisherman, Martin Cleary, who has parlayed his experience with a rod and reel into Parkinson’s, ALS and Alzheimer’s and Cardiovascular Disease research. Sounds about right, doesn't it? Looks like Mr. Cleary has forgone baiting a hook for baiting suckers into a Pump and Dump scheme.
This coming weekend, our website will undergone the first of a series of a series of updates towards its new look. As a result, it will be down from time to time between Friday's close and Monday's open. We think you'll find the new website to be more informative as we strive towards our goal of educating the world about scoundrels and the schemes they concoct towards the goal of taking your money.
Alert:
At least one paid tout is sending emails promoting ACYD.
We classify this as a pump and dump.
Alert:
At least two paid touts are sending emails promoting CXLT.
We classify this as a pump and dump.
Alert:
At least four paid touts are sending emails promoting AMBS.
We classify this as a pump and dump.
Alert:
At least three paid touts are sending emails promoting BZRT.
We classify this as a pump and dump.
Alert:
At least one paid tout is sending emails promoting RCLL.
We classify this as a pump and dump.
Alert:
At least one paid tout is sending emails promoting FDMF.
We classify this as a pump and dump.
Alert:
At least one paid tout is sending emails promoting AAAA.
We classify this as a pump and dump.